Therapeutics of Alzheimer's disease: Past, present and future
The DOI matches its Crossref record; 406 of the 406 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992 · cited 1×
“At least 7 caspases (caspases-1, 2, 3, 6, 8, 9, and 12) are implicated in Ab mediated neuronal death, of which, caspase 6 is the best known (Nikolaev et al., 2009).”
BackgroundRetractedGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“Curcumin decreases Abinduced inflammation and modestly inhibits b-secretase and AChE (Yang et al., 2005).”
BackgroundBuée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,015
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“Combination of vitamin E with donepezil did not provide additional benefit in patients with AD or mild cognitive impairment (Petersen et al., 2005).”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 1×
“The greatest risk factor is advancing age; others being a positive family history, head trauma, female gender, previous depression, diabetes mellitus, hyperlipidemia and vascular factors (Kivipelto et al., 2001).”
BackgroundLim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 3×
“Although following vaccination, the subjects showed a slowed cognitive decline and superior plaque clearance it did not stop their progression to severe stages (Holmes et al., 2008).”
BackgroundInfluentialShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 3×
“With age, LRP expression decreases, impairing Ab efflux contributing to prolonged Ab stay in the brain (Shibata et al., 2000).”
BackgroundTariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Protein S-nitrosylation: a physiological signal for neuronal nitric oxide
Jaffrey, S. R., Erdjument-Bromage, H., Ferris, C. D., Tempst, P., & Snyder, S. H. (2001) · Nature Cell Biology · doi:10.1038/35055104 · Cited by 1,401
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“During the trial about 6% of subjects developed meningoencephalitis hence, was discontinued (Orgogozo et al., 2003).”
BackgroundMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 1×
“users (Cornelius et al., 2004; Lindsay et al., 2002), but data from most clinical trials in AD andmild cognitive impairment have either”
MethodImpaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173 · cited 1×
“MitoQ selectively accumulates in the organelle, continually recycled by mitochondrial enzymes, and it can function even in the absence of an intact ETC, which makes it a potent antioxidant compared to the untargeted ones (Murphy and Smith, 2007).”
BackgroundMcShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
Bioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051 · cited 1×
“Similar could be the case with resveratrol; due to an extensive first pass metabolism, the bioavailable concentration of resveratrol is only about 1% (Walle, 2011).”
BackgroundA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 971
Zandi, P. P. (2002) · JAMA · doi:10.1001/jama.288.17.2123 · Cited by 906
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Brain inflammation and adult neurogenesis: The dual role of microglia
Ekdahl, C. T., Kokaia, Z., & Lindvall, O. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.052 · Cited by 801
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 2×
“Lithium and valproate have inhibitory actions on GSK3 and when administered they reduce tau pathology in transgenic mice (Engel et al., 2006; Noble et al., 2005).”
BackgroundThe role of microglia in amyloid clearance from the AD brain
Lee, C. Y. D., & Landreth, G. E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0433-4 · Cited by 701
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · cited 1×
“Heat shock protein 90 (Hsp 90), a chaperone involved in folding the denatured proteins, seems to play a role in preventing tau degradation (Dickey et al., 2007).”
BackgroundNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634 · cited 1×
“Tarenflurbil, the enantiomer of flurbiprofen modulates the g-secretase activity and thereby reduce Ab levels (Eriksen et al., 2003).”
BackgroundDeane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 1×
“The studies with the compound has demonstrated significant blood brain barrier clearance, reduced amyloid deposition, and improved cognitive and cerebrovascular parameters in transgenic mice (Deane et al., 2012).”
BackgroundSnow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Baum, L., Lam, C. W. K., Cheung, S. K.-K., Kwok, T., Lui, V., Tsoh, J., Lam, L., Leung, V., Hui, E., Ng, C., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160862c · Cited by 592
Aisen, P. S. (2008) · JAMA · doi:10.1001/jama.300.15.1774 · Cited by 557
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · cited 2×
“Volumetric imaging in the vaccine responders at 10e11 months showed an accelerated brain and hippocampal volume loss, but there was no reduction in cognitive scores (Fox et al., 2005).”
BackgroundThe significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area.
Orgogozo, J. M., Dartigues, J. F., Lafont, S., Letenneur, L., Commenges, D., Salamon, R., Renaud, S., & Breteler, M. M. B. (1997) · PubMed · Cited by 523
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey II, W. H., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13309 · Cited by 521
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 1×
“The phase III trials did not show significant differences in the primary endpoint irrespective of the APOE 34 genotype, but they had a high incidence of amyloid related imaging abnormalities (Sperling et al., 2012).”
BackgroundElectron transport chain defects in Alzheimer's disease brain
Parker, W. D., BA, J. P., Filley, C. M., & Kleinschmidt-DeMasters, B. K. (1994) · Neurology · doi:10.1212/wnl.44.6.1090 · Cited by 494
Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H.-L., Beal, M. F., & Gibson, G. E. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.008 · Cited by 485
Cotinine disposition and effects
Benowitz, N. L., Kuyt, F., Jacob, P., Jones, R. T., & Osman, A.-L. (1983) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1983.222 · Cited by 484
Nutraceutical Antioxidants as Novel Neuroprotective Agents
Kelsey, N. A., Wilkins, H. M., & Linseman, D. A. (2010) · Molecules · doi:10.3390/molecules15117792 · Cited by 480
Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., Szeto, H. H., Park, B., & Reddy, P. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100564 · Cited by 469
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1×
“Gantenerumab preferentially interacts with aggregated Ab in the brain without affecting plasma Ab levels suggesting its systemic specificity (Bohrmann et al., 2012); the effect is dose dependent (Ostrowitzki et al., 2012).”
BackgroundLue, L.-F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., Stern, D. M., & Yan, S. D. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7732 · Cited by 439
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 2×
“, 2012); the effect is dose dependent (Ostrowitzki et al., 2012).”
BackgroundMidlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Shibasaki, H., Kume, T., & Akaike, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008035200 · Cited by 415
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · cited 2×
“taxel to tau-transgenic mice improves fast axonal transport, microtubule density and motor function (Zhang et al., 2005).”
BackgroundSmall molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 1×
“inducing differentiation and augmenting synaptic function (Massa et al., 2010).”
Vellas, B., Coley, N., Ousset, P.-J., Berrut, G., Dartigues, J.-F., Dubois, B., Grandjean, H., Pasquier, F., Piette, F., Robert, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70206-5 · Cited by 398
Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice
Marr, R. A., Rockenstein, E., Mukherjee, A., Kindy, M. S., Hersh, L. B., Gage, F. H., Verma, I. M., & Masliah, E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-01992.2003 · Cited by 392
Mechanisms of excitotoxicity in neurologic diseases
Beal, M. F. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.15.1464368 · Cited by 388
Chalmers, D. T., & Watson, S. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)90748-k · Cited by 387
Rofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 385
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia
Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D., & Pasinetti, G. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.588 · Cited by 378
Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377 · cited 2×
“reduction in oxidative stress, but other groups did not show changes (Galasko et al., 2012).”
BackgroundClearance of amyloid-β by circulating lipoprotein receptors
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1635 · Cited by 373
Dall'Igna, O. P., Fett, P., Gomes, M. W., Souza, D. O., Cunha, R. A., & Lara, D. R. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.008 · Cited by 372
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease
Sanchez-Mejia, R. O., Newman, J. W., Toh, S., Yu, G.-Q., Zhou, Y., Halabisky, B., Cissé, M., Scearce-Levie, K., Cheng, I. H., Gan, L., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2213 · Cited by 369
S-Nitrosylation of mitochondrial caspases
Mannick, J. B., Schonhoff, C., Papeta, N., Ghafourifar, P., Szibor, M., Fang, K., & Gaston, B. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104008 · Cited by 363
Joseph, J. A., Arendash, G., Gordon, M., Diamond, D., Shukitt-Hale, B., Morgan, D., & Denisova, N. A. (2003) · Nutritional Neuroscience · doi:10.1080/1028415031000111282 · Cited by 362
APOE genotype-specific differences in the innate immune response
Vitek, M. P., Brown, C. M., & Colton, C. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.014 · Cited by 362
Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.-M., Suemoto, T., Higuchi, M., & Saido, T. C. (2005) · Nature Medicine · doi:10.1038/nm1206 · Cited by 361
Javed, H., Khan, M. M., Ahmad, A., Vaibhav, K., Ahmad, M. E., Khan, A., Ashafaq, M., Islam, F., Siddiqui, M. S., Safhi, M. M., et al. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.046 · Cited by 357
Canas, P. M., Porciúncula, L. O., Cunha, G. M. A., Silva, C. G., Machado, N. J., Oliveira, J. M. A., Oliveira, C. R., & Cunha, R. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3728-09.2009 · Cited by 357
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 351
Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease
Maczurek, A., Hager, K., Kenklies, M., Sharman, M., Martins, R., Engel, J., Carlson, D. A., & Münch, G. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.015 · Cited by 346
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Puzzo, D., Staniszewski, A., Deng, S. X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D. W., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0864-09.2009 · Cited by 331
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 331
RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice
Arancio, O., Zhang, H. P., Chen, X., Lin, C., Trinchese, F., Puzzo, D., Liu, S., Hegde, A., Yan, S. F., Stern, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600415 · Cited by 328
Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3059-10.2010 · Cited by 320
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
Dodel, R. C. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317
Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 310
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000224350.82719.83 · Cited by 307
Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · cited 1×
“Passive immunization approach with monoclonal antibodies against phosphorylated tau molecules also show benefit in tau transgenic animal models (Boutajangout et al., 2011; Chai et al., 2011).”
Background18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory
KING, M., MARSDEN, C., & FONE, K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.07.001 · Cited by 304
Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Xu, Y., Yan, J., Zhou, P., Li, J., Gao, H., Xia, Y., & Wang, Q. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.02.002 · Cited by 301
Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297 · cited 3×
“…inhibiting amyloid aggregation (Necula et al., 2007), improving electron transport, decreasing oxidative stress, prevent mitochondrial damage (Atamna et al., 2008), regulate autophagy (Congdon et al., 2012) and inhibition of AChE (Pfaffendorf et al., 1997) and hsp70 activity (Jinwal et al., 2009).”
BackgroundAisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 295
Atwood, C. S., Obrenovich, M. E., Liu, T., Chan, H., Perry, G., Smith, M. A., & Martins, R. N. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00174-7 · Cited by 293
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110190 · Cited by 292
Alzheimer disease, the two-hit hypothesis: An update
Zhu, X., Lee, H.-G., Perry, G., & Smith, M. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.014 · Cited by 292
Smith, A., Giunta, B., Bickford, P. C., Fountain, M., Tan, J., & Shytle, R. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.012 · Cited by 280
Amount and type of alcohol and risk of dementia: The Copenhagen City Heart Study
Truelsen, T., Thudium, D., & Grønbæk, M. (2002) · Neurology · doi:10.1212/01.wnl.0000031421.50369.e7 · Cited by 280
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 280
Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease
Schneider, L. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.69 · Cited by 275
Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N., Greengard, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701055104 · Cited by 274
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272 · cited 2×
“A number of investigators have looked at the possible advantage of its combining memantine with AChEI in AD (Atri et al., 2013; Dantoine et al., 2006; Howard et al., 2012; Lopez et al., 2009; Porsteinsson et al., 2008; Riepe et al., 2007; Tariot et al., 2004).”
BackgroundMethylene Blue Delays Cellular Senescence and Enhances Key Mitochondrial Biochemical Pathways
Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., & Ames, B. N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9610com · Cited by 272
Developing β‐secretase inhibitors for treatment of Alzheimer’s disease
Ghosh, A. K., Brindisi, M., & Tang, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07476.x · Cited by 272
Substrate specificity of γ-secretase and other intramembrane proteases
Beel, A. J., & Sanders, C. R. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7462-2 · Cited by 269
The Glutamatergic System and Alzheimer???s Disease: Therapeutic Implications
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 267
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · cited 1×
“A number of investigators have looked at the possible advantage of its combining memantine with AChEI in AD (Atri et al., 2013; Dantoine et al., 2006; Howard et al., 2012; Lopez et al., 2009; Porsteinsson et al., 2008; Riepe et al., 2007; Tariot et al., 2004).”
BackgroundRogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 265
The serotonergic system in ageing and Alzheimer's disease
Rodríguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 264
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Olcese, J. M., Cao, C., Mori, T., Mamcarz, M. B., Maxwell, A., Runfeldt, M. J., Wang, L., Zhang, C., Lin, X., Zhang, G., et al. (2009) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2009.00692.x · Cited by 260
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid
Kanninen, K., Malm, T. M., Jyrkkänen, H.-K., Goldsteins, G., Keksa-Goldsteine, V., Tanila, H., Yamamoto, M., Ylä-Herttuala, S., Levonen, A.-L., & Koistinaho, J. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.07.010 · Cited by 255
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255
Wilcock, G. K., Ballard, C. G., Cooper, J. A., & Loft, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0302 · Cited by 253
Alternative Mitochondrial Electron Transfer as a Novel Strategy for Neuroprotection
Wen, Y., Li, W., Poteet, E. C., Xie, L., Tan, C., Yan, L.-J., Ju, X., Liu, R., Qian, H., Marvin, M. A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208447 · Cited by 251
Extracellular Redox State: Refining the Definition of Oxidative Stress in Aging
Jones, D. P. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.169 · Cited by 241
The cholinergic system and hippocampal plasticity
Drever, B. D., Riedel, G., & Platt, B. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.037 · Cited by 240 · cited 1×
“The cholinergic AChRs are expressed on principal and inhibitory interneurons, both pre- as well as post-synaptically in most regions of hippocampus; thus, boosting acetylcholine levels in the synaptic cleft can have bidirectional influences (Drever et al., 2011).”
BackgroundA phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S., Walsh, S., Little, J. T., Behan, K., Reynolds, B., Ward, C., Jin, S., Thomas, R., Aisen, P. S., & Study, F. T. A. D. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318216eb7b · Cited by 240
A Nitric Oxide Signaling Pathway Controls CREB-Mediated Gene Expression in Neurons
Riccio, A., Alvania, R. S., Lonze, B. E., Ramanan, N., Kim, T., Huang, Y., Dawson, T. M., Snyder, S. H., & Ginty, D. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2005.12.006 · Cited by 240
Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235
Going new places using an old MAP: tau, microtubules and human neurodegenerative disease
Garcia, M. L., & Cleveland, D. W. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00172-1 · Cited by 235
Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234 · cited 2×
“from baseline in the treated group (Blennow et al., 2012).”
BackgroundHirst, W. D., Stean, T. O., Rogers, D. C., Sunter, D., Pugh, P., Moss, S. F., Bromidge, S. M., Riley, G., Smith, D. R., Bartlett, S., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.049 · Cited by 234
Lee, D., Long, S. A., Adams, J. L., Chan, G., Vaidya, K. S., Francis, T. A., Kikly, K., Winkler, J. D., Sung, C.-M., Debouck, C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16007 · Cited by 234
Banerjee, S., Hellier, J., Romeo, R., Dewey, M., Knapp, M., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., et al. (2013) · Health Technology Assessment · doi:10.3310/hta17070 · Cited by 233
Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability
Jinwal, U. K., Miyata, Y., Koren, J., Jones, J. R., Trotter, J. H., Chang, L., O'Leary, J., Morgan, D., Lee, D. C., Shults, C. L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3345-09.2009 · Cited by 228
Yasojima, K., McGeer, E. G., & McGeer, P. L. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03008-6 · Cited by 226
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · cited 2×
“Lithium and valproate have inhibitory actions on GSK3 and when administered they reduce tau pathology in transgenic mice (Engel et al., 2006; Noble et al., 2005).”
BackgroundChronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease
Tariot, P. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.72 · Cited by 223
Lloret, A., Badía, M.-C., Mora, N. J., Pallardó, F. V., Alonso, M.-D., & Viña, J. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1033 · Cited by 222
Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Sanz-Blasco, S., Valero, R. A., Rodríguez-Crespo, I., Villalobos, C., & Núñez, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002718 · Cited by 219
Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer
BACHURIN, S., BUKATINA, E., LERMONTOVA, N., TKACHENKO, S., AFANASIEV, A., GRIGORIEV, V., GRIGORIEVA, I., IVANOV, Y., SABLIN, S., & ZEFIROV, N. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03654.x · Cited by 219
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Methylene Blue Inhibits Amyloid Aβ Oligomerization by Promoting Fibrillization
Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., & Glabe, C. G. (2007) · Biochemistry · doi:10.1021/bi700411k · Cited by 213
Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata-Fukae, C., Li, H.-F., Feng, L., Lecanu, L., Walker, B. R., Planel, E., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130526 · Cited by 213
Bösel, J., Gandor, F., Harms, C., Synowitz, M., Harms, U., Djoufack, P. C., Megow, D., Dirnagl, U., Hörtnagl, H., Fink, K. B., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02980.x · Cited by 210
Ma, Q.-L., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Teng, E., Hu, S., Chen, P.-P., Maiti, P., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393751 · Cited by 210
RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Yan, S., Chen, X., Walker, D., Schmidt, A., Arancio, O., & Lue, L.-F. (2007) · Current Molecular Medicine · doi:10.2174/156652407783220741 · Cited by 207
Shaw, K. T. Y., Utsuki, T., Rogers, J., Yu, Q.-S., Sambamurti, K., Brossi, A., Ge, Y.-W., Lahiri, D. K., & Greig, N. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131152998 · Cited by 205
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Prickaerts, J., van Goethem, N. P., Chesworth, R., Shapiro, G., Boess, F. G., Methfessel, C., Reneerkens, O. A. H., Flood, D. G., Hilt, D., Gawryl, M., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.024 · Cited by 204
Clinical Aspects of Melatonin Intervention in Alzheimers Disease Progression
P. Cardinali, D., M. Furio, A., & I. Brusco, L. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246209 · Cited by 204
Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. D. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 203
A possible role for lutein and zeaxanthin in cognitive function in the elderly
Johnson, E. J. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.034611 · Cited by 202
Weksler, M. E., Relkin, N., Turkenich, R., LaRusse, S., Zhou, L., & Szabo, P. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00029-3 · Cited by 201
Aracava, Y., Pereira, E. F. R., Maelicke, A., & Albuquerque, E. X. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077172 · Cited by 200
Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., & Parsons, C. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01872-9 · Cited by 200
Lu, P. H., Masterman, D. A., Mulnard, R., Cotman, C., Miller, B., Yaffe, K., Reback, E., Porter, V., Swerdloff, R., & Cummings, J. L. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.nct50002 · Cited by 197
Siemers, E. R., Friedrich, S., Dean, R. A., Gonzales, C. R., Farlow, M. R., Paul, S. M., & DeMattos, R. B. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cb577a · Cited by 192
GABAAreceptors in aging and Alzheimer’s disease
Rissman, R. A., De Blas, A. L., & Armstrong, D. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04832.x · Cited by 192
Lee, J.-Y., Friedman, J. E., Angel, I., Kozak, A., & Koh, J.-Y. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.01.005 · Cited by 191
Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice
Casadesus, G., Webber, K. M., Atwood, C. S., Pappolla, M. A., Perry, G., Bowen, R. L., & Smith, M. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.01.008 · Cited by 191
Dodel, R., Rominger, A., Bartenstein, P., Barkhof, F., Blennow, K., Förster, S., Winter, Y., Bach, J.-P., Popp, J., Alferink, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70014-0 · Cited by 187
Nonsteroidal Anti-Inflammatory Drugs Promote Axon Regeneration via RhoA Inhibition
Fu, Q., Hue, J., & Li, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4353-06.2007 · Cited by 183
Pharmacodynamics of Memantine: An Update
Parsons, C., Rammes, G., & Danysz, W. (2008) · Current Neuropharmacology · doi:10.2174/157015908783769671 · Cited by 183
Reynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parties, H., Eglen, R. M., & Wong, E. H. F. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13303.x · Cited by 180
Open-Channel Blockers at the Human α4β2 Neuronal Nicotinic Acetylcholine Receptor
Buisson, B., & Bertrand, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.3.555 · Cited by 179
Oliveira, T. G., Chan, R. B., Tian, H., Laredo, M., Shui, G., Staniszewski, A., Zhang, H., Wang, L., Kim, T.-W., Duff, K. E., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3317-10.2010 · Cited by 179
Martone, R. L., Zhou, H., Atchison, K. P., Comery, T. A., Xu, J. Z., Huang, X., Gong, X., Jin, M., Kreft, A. F., Harrison, B. L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152975 · Cited by 179
Cordle, A., & Landreth, G. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2544-04.2005 · Cited by 178
Liu, G., Men, P., Harris, P. L. R., Rolston, R. K., Perry, G., & Smith, M. A. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.020 · Cited by 178
Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein
Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178
Chronic divalproex sodium use and brain atrophy in Alzheimer disease
Fleisher, A. S., Truran, D., Mai, J. T., Langbaum, J. B. S., Aisen, P. S., Cummings, J. L., Jack, C. R., Weiner, M. W., Thomas, R. G., Schneider, L. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a16c · Cited by 177
Karanth, S., Lyson, K., & McCann, S. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3383 · Cited by 176
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174 · cited 2×
“A study using a cocktail of different pathological epitopes showed a strong reduction in tau pathology in two different animal models without significant adverse effects (Boimel et al., 2010).”
BackgroundHu, S., Begum, A. N., Jones, M. R., Oh, M. S., Beech, W. K., Beech, B. H., Yang, F., Chen, P., Ubeda, O. J., Kim, P. C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.007 · Cited by 174
Fisher, A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.002 · Cited by 174
Jan, A., Adolfsson, O., Allaman, I., Buccarello, A.-L., Magistretti, P. J., Pfeifer, A., Muhs, A., & Lashuel, H. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172411 · Cited by 173
Sayas, C. L., Moreno-Flores, M. T., Avila, J., & Wandosell, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37046 · Cited by 172
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Oleuropein and derivatives from olives as Tau aggregation inhibitors
Daccache, A., Lion, C., Sibille, N., Gerard, M., Slomianny, C., Lippens, G., & Cotelle, P. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.02.010 · Cited by 168
Lipoproteins in the Central Nervous System
LADU, M. J., REARDON, C., VAN ELDIK, L., FAGAN, A. M., BU, G., HOLTZMAN, D., & GETZ, G. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06365.x · Cited by 167
The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
Badiola, N., Alcalde, V., Pujol, A., Münter, L.-M., Multhaup, G., Lleó, A., Coma, M., Soler-López, M., & Aloy, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058837 · Cited by 165
Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin
Kwiatkowski, D., Mehl, R., & Yin, H. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.2.375 · Cited by 164
Youdim, M. B. H., & Weinstock, M. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1015131516649 · Cited by 164
Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J. M., & Parsons, C. G. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.051 · Cited by 163 · cited 1×
“metabotropic mGluR5 receptors (MPEP) protect neurons from Ab toxicity (Rammes et al., 2011).”
BackgroundEffect of Intranasal Insulin on Cognitive Function: A Systematic Review
Shemesh, E., Rudich, A., Harman-Boehm, I., & Cukierman-Yaffe, T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1802 · Cited by 162
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162 · cited 1×
“progression for up to 2 years (Gutzmann and Hadler, 1998), a subsequent study found no significant effect (Thal et al.”
BackgroundMatsuoka, Y., Gray, A. J., Hirata-Fukae, C., Minami, S. S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 161
Sabbagh, M. N., Agro, A., Bell, J., Aisen, P. S., Schweizer, E., & Galasko, D. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318204b550 · Cited by 160
Corrada, M. M., Kawas, C. H., Hallfrisch, J., Muller, D., & Brookmeyer, R. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.001 · Cited by 159
Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 159
Eriksdotter-Jönhagen, M., Linderoth, B., Lind, G., Aladellie, L., Almkvist, O., Andreasen, N., Blennow, K., Bogdanovic, N., Jelic, V., Kadir, A., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000336051 · Cited by 158
Hanyu, H., Sato, T., Kiuchi, A., Sakurai, H., & Iwamoto, T. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02067.x · Cited by 158
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 154
Simvastatin enhances learning and memory independent of amyloid load in mice
Li, L., Cao, D., Kim, H., Lester, R., & Fukuchi, K. (2006) · Annals of Neurology · doi:10.1002/ana.21053 · Cited by 150
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
Salehi, B., Machin, L., Monzote, L., Sharifi-Rad, J., Ezzat, S. M., Salem, M. A., Merghany, R. M., El Mahdy, N. M., Kılıç, C. S., Sytar, O., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01818 · Cited by 707
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Metadata
- Authors
- Anand, R., Gill, K. D., & Mahdi, A. A.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 76
- Pages
- 27-50
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2003109394
- Cited by
- 747
- References
- 406
- FWCI
- 27.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.